A tumor cord model for Doxorubicin delivery and dose optimization in solid tumors

Theoretical Biology and Medical Modelling

Volumn 6, Issue 1, 2009, Pages

  Eikenberry, Steffen ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; CANCER CELL; CARDIOTOXICITY; CELL DEATH; CELL SURVIVAL; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG PENETRATION; DRUG TRANSPORT; MAXIMUM PLASMA CONCENTRATION; MICROENVIRONMENT; MORTALITY; SOLID TUMOR; TUMOR MODEL; TUMOR VASCULARIZATION; ANIMAL; BIOLOGICAL MODEL; BLOOD; CELL COUNT; DRUG EFFECT; EXTRACELLULAR SPACE; HUMAN; INTRACELLULAR SPACE; METABOLISM; NEOPLASM; PATHOLOGY; TIME;

ANIMALS; CELL COUNT; CELL DEATH; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG DELIVERY SYSTEMS; EXTRACELLULAR SPACE; HUMANS; INTRACELLULAR SPACE; MODELS, BIOLOGICAL; NEOPLASMS; TIME FACTORS;

EID: 69849096664     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-6-16     Document Type: Article

References (54)

1. Adriamycin-induced myocardial toxicity: New solutions for an old problem? D Outomuro DR Grana F Azzato J Milei, Int J Cardiol 2007 117 6 15 10.1016/j.ijcard.2006.05.005 16863672 (Pubitemid 46399979)
2. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. DA Gewirtz, Biochem Pharmacol 1999 57 727 741 10.1016/S0006-2952(98)00307-4 10075079 (Pubitemid 29094544)
3. A Mathematical Model for Comparison of Bolus Injection, Continuous Infusion, and Liposomal Delivery of Doxorubicin to Tumor Cells. AW El-Kareh TW Secomb, Neoplasia 2000 2 325 338 10.1038/sj.neo.7900096 11005567
4. Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. AW El-Kareh TW Secomb, Neoplasia 2005 7 705 713 10.1593/neo.05118 16026650 (Pubitemid 41099424)
5. Drug penetration in solid tumours. AI Minchinton IF Tannock, Nat Rev Cancer 2006 6 583 592 10.1038/nrc1893 16862189 (Pubitemid 44140857)
6. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. SS Legha RS Benjamin B Mackay M Ewer S Wallace M Valdivieso SL Rasmussen GR Blumenschein EJ Freireich, Ann Intern Med 1982 96 133 139 7059060
7. The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors. AJ Primeau A Rendon D Hedley L Lilge IF Tannock, Clin Cancer Res 2005 11 8782 8788 10.1158/1078-0432.CCR-05-1664 16361566 (Pubitemid 43005929)
8. A model of fluid flow in solid tumors. C Pozrikidis DA Farrow, Ann Biomed Eng 2003 31 181 94 10.1114/1.1540103 12627826
9. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. LT Baxter RK Jain, Microvasc Res 1989 37 77 104 10.1016/0026-2862(89)90074-5 2646512 (Pubitemid 19045527)
10. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. LT Baxter RK Jain, Microvasc Res 1990 40 246 63 10.1016/0026-2862(90)90023-K 2250603 (Pubitemid 20327678)
11. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. LT Baxter RK Jain, Microvasc Res 1991 41 5 23 10.1016/0026-2862(91) 90003-T 2051954
12. Understanding the role of the tumour vasculature in the transport of drugs to solid cancer tumours. NS Wijeratne KA Hoo, Cell Prolif 2007 40 283 301 10.1111/j.1365-2184.2007.00436.x 17531075 (Pubitemid 46802185)
13. Regression and Regrowth of Tumour Cords Following Single-Dose Anticancer Treatment. A Bertuzzi A D'Onofrio A Fasano A Gandolfi, Bull Math Biol 2003 65 903 931 10.1016/S0092-8240(03)00054-5 12909255 (Pubitemid 37029238)
14. A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. TL Jackson HM Byrne, Math Biosci 2000 164 17 38 10.1016/S0025-5564(99)00062-0 10704636 (Pubitemid 30159958)
15. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. AW El-Kareh TW Secomb, Neoplasia 2004 6 117 127 10.1593/neo.03205 15140400 (Pubitemid 38544599)
16. Intracellular Accumulation and Mechanism of Action of Doxorubicin in a Spatio-temporal Tumor Model. TL Jackson, J Theor Biol 2003 220 201 213 10.1006/jtbi.2003.3156 12468292 (Pubitemid 36027125)
17. A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results. B Ribba K Marron Z Agur T Alarcn PK Maini, Bull Math Biol 2005 67 79 99 10.1016/j.bulm.2004.06.007 15691540 (Pubitemid 40181069)
18. Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. JP Sinek S Sanga X Zheng HB Frieboes M Ferrari V Cristini, J Math Biol 2009 58 485 510 10.1007/s00285-008-0214-y 18781304
19. Explicit separation of growth and motility in a new tumor cord model. CJ Thalhauser T Sankar MC Preul Y Kuang, Bull Math Biol 2009 71 585 601 10.1007/s11538-008-9372-8 19067082
20. Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. J Robert A Illiadis B Hoerni JP Cano M Durand C Lagarde, Eur J Cancer Clin Oncol 1982 18 739 45 10.1016/0277-5379(82)90072-4 6891324 (Pubitemid 12033227)
21. Transport of molecules across tumor vasculature. RK Jain, Cancer Metastasis Rev 1987 6 559 593 10.1007/BF00047468 3327633
22. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. RF Greene JM Collins JF Jenkins JL Speyer CE Myers, Cancer Res 1983 43 3417 21 6850648
23. Comparative intracellular uptake of adriamycin and 4'-deoxydoxorubicin by nonsmall cell lung tumor cells in culture and its relationship to cell survival. DJ Kerr AM Kerr IR Freshney SB Kaye, Biochem Pharmacol 1986 35 2817 2823 10.1016/0006-2952(86)90195-4 3741470 (Pubitemid 16051530)
24. Pharmacokinetic study of i.v. infusions of adriamycin. S Eksborg HS Strandler F Edsmyr I Näslund P Tahvanainen, Eur J Clin Pharmacol 1985 28 205 12 10.1007/BF00609693 3987800 (Pubitemid 15143785)
25. Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. T Skovsgaard, Biochem Pharmacol 1978 27 1221 1227 10.1016/0006-2952(78)90455-0 567991 (Pubitemid 8393263)
26. A Fickian diffusion transport process with features of transport catalysis. Doxorubicin transport in human red blood cells. M Dalmark HH Storm, J Gen Physiol 1981 78 349 364 10.1085/jgp.78.4.349 7288392 (Pubitemid 11020899)
27. Delivery of molecular and cellular medicine to solid tumors. RK Jain, Adv Drug Deliv Rev 2001 46 149 168 10.1016/S0169-409X(00)00131-9 11259838
28. Microvascular Architecture in a Mammary Carcinoma: Branching Patterns and Vessel Dimensions. JR Less TC Skalak EM Sevick RK Jain, Cancer Res 1991 51 265 273 1988088
29. Interstitial Fluid Pressure and Capillary Diameter Distribution in Human Melanoma Xenografts. I Tufto EK Rofstad, Microvasc Res 1999 58 205 214 10.1006/mvre.1999.2184 10527764 (Pubitemid 29531870)
30. Microvascular permeability of normal and neoplastic tissues. LE Gerlowski RK Jain, Microvasc Res 1986 31 288 305 10.1016/0026-2862(86)90018-X 2423854 (Pubitemid 16076428)
31. Morphometric analyses of the microvasculature of tumors during growth and after x-irradiation. DE Hilmas EL Gillette, Cancer 1974 33 103 10 10.1002/1097-0142(197401)33:1<103::AID-CNCR28203301163.0.CO;2-7 4810083
32. Tumour cords in 52 human bronchial and cervical squamous cell carcinomas: inferences for their cellular kinetics and radiobiology. JV Moore PS Hasleton CH Buckley, Br J Cancer 1985 51 407 413 3970817
33. Extravascular diffusion in normal and neoplastic tissues. LJ Nugent RK Jain, Cancer Res 1984 44 238 44 6197161
34. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Y Boucher RK Jain, Cancer Res 1992 52 5110 4 1516068
35. Interstitial fluid pressure in DMBA-induced rat mammary tumours. H Wiig E Tveit R Hultborn RK Reed L Weiss, Scand J Clin Lab Invest 1982 42 159 164 6813944
36. Oncotic pressure in solid tumors is elevated. M Stohrer Y Boucher M Stangassinger RK Jain, Cancer Res 2000 60 4251 5 10945638
37. Integral-mass balance method for determination of solvent drag reflection coefficient. MB Wolf PD Watson DR Scott 2nd, Am J Physiol 1987 253 H194 204 3605366
38. Vascular permeability and transvascular fluid and protein transport in the dog lung. JC Parker RE Parker DN Granger AE Taylor, Circ Res 1981 48 549 61 7460224
39. Reflection coefficients of dog lung endothelium to small hydrophilic solutes. W Perl P Chowdhury FP Chinard, Am J Physiol 1975 228 797 809 1115245
40. Measurement of capillary filtration coefficient in a solid tumor. EM Sevick RK Jain, Cancer Res 1991 51 1352 5 1997172
41. Measurement of material extravasation in microvascular networks using fluorescence video-microscopy. NZ Wu B Klitzman G Rosner D Needham MW Dewhirst, Microvasc Res 1993 46 231 253 10.1006/mvre.1993.1049 8246821
42. Permeability of single capillaries to intermediate-sized colored solutes. FE Curry VH Huxley RH Adamson, Am J Physiol 1983 245 H495 505 6604463
43. Multiple pathways of capillary permeability. EM Renkin, Circ Res 1977 41 735 43 923024
44. Diffusion and Convection in Normal and Neoplastic Tissues. EA Swabb J Wei PM Cullino, Cancer Res 1974 34 2814 2822 4369924
45. A nuclear magnetic resonance study of the self-association of adriamycin and daunomycin in aqueous solution. IJ McLennan RE Lenkinski Y Yanuka, Can J Chem 1985 63 1233 1238 10.1139/v85-210
46. Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. SR Chary RK Jain, Proc Natl Acad Sci USA 1989 86 5385 9 10.1073/pnas.86.14.5385 2748592
47. The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. H Wiig CC Gyenge O Tenstad, J Physiol 2005 567 557 67 10.1113/jphysiol.2005.089615 15994186 (Pubitemid 41301051)
48. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. RK Jain, Science 2005 307 58 62 10.1126/science.1104819 15637262 (Pubitemid 40093472)
49. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. ES Casper JJ Gaynor SI Hajdu GB Magill C Tan C Friedrich MF Brennan, Cancer 1991 68 1221 1229 10.1002/1097-0142(19910915)68:6<1221::AID-CNCR28206806073.0.CO;2-R 1873773
50. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. GN Hortobagyi D Frye AU Buzdar MS Ewer G Fraschini V Hug F Ames E Montague CH Carrasco B Mackay RS Benjamin, Cancer 1989 63 37 45 10.1002/1097-0142(19890101)63:1<37::AID-CNCR28206301063.0.CO;2-Z 2910423
51. Limited Penetration of Anticancer Drugs through Tumor Tissue: A Potential Cause of Resistance of Solid Tumors to Chemotherapy. IF Tannock CM Lee JK Tunggal DS Cowan MJ Egorin, Clin Cancer Res 2002 8 878 884 11895922
52. Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. RF Ozols JK Willson MD Weltz KR Grotzinger CE Myers RC Young, Cancer Res 1980 40 4109 12 7471054
53. A mathematical model for cisplatin cellular pharmacodynamics. AW El-Kareh TW Secomb, Neoplasia 2003 5 161 169 12659689
54. Preliminary pharmacokinetic model for adriamycin (NSC-123127). PA Harris JF Gross, Cancer Chemother Rep 1975 59 819 25 1175172